2Moustafa RR, Baron JC. Pathophysiology of ischemic stroke: insights from imaging, and implications for therapy and drug discovery. Br J Pharmacol,2008,153 Suppl 1 : S44-54.
3American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics:2007 update. Circulation,2007, 115 : e69-171.
4Muir KW, Buchan A, yon Kummer R, et al. Imaging of acute stroke. Lancet Neurology ,2006,5:755-768.
5Abciximab Emergent Stroke Treatment Trial ( AbESTT ) Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke, 2005, 36:880-890.
6Hacke W, Albers G, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase Ⅱ MPd-based 9-hour window acute stroke thmmbolysis trial with intravenous desmoteplase. Stroke, 2005, 36: 66-73.
7Furlan A J, Eyding D, Albers GW, et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS) : evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke,2006, 37: 1227-1231.
8Montiel NH, Rosso C, Chupin N, et al. Automatic prediction of infarct growth in acute ischemie stroke from MR apparent diffusion coefficient maps. Acad Radiol ,2008,15:77-83.
9Moustafa RR, Baron JC. Pathophysiology of ischemic stroke: insights from imaging, and implications for therapy and drug discovery [J] . Br J Pharmacol, 2008, 153 (1): 44-54.
10American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics: 2007 update[M].Circulation, 2007, 115:69 -171.
